HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: exploration of real-world outcomes
-
Published:2024-06
Issue:
Volume:4
Page:100056
-
ISSN:2949-8198
-
Container-title:ESMO Gastrointestinal Oncology
-
language:en
-
Short-container-title:ESMO Gastrointestinal Oncology
Author:
Chakrabarti S.ORCID,
Bucheit L.ORCID,
Saha J.,
Clemens K.,
Barnett R.ORCID,
Zhang N.,
Mahipal A.ORCID
Reference29 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021
3. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer;Van Cutsem;Gastric Cancer,2015
4. Molecular pathways and mechanisms of HER2 in cancer therapy;Raghav;Clin Cancer Res,2023
5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010